COMPANY PROFILE

Genticel

Explore full profile

French HPV therapeutic vaccine biotech (ex-BT Pharma / Pasteur lineage)

Labège, FranceFounded 2001Biotech & Life Sciences

Valuation $25–50M Last recorded · 2020

Revenue <$1M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Genticel

Genticel (formerly BT Pharma SA) is a French biotechnology company spun out around Pasteur Institute science to develop therapeutic vaccines against HPV for women already infected, aiming to prevent cervical cancer progression. Founded as BT Pharma and later listed/rebranded as Genticel (Labège, Occitanie), the company focused on immunotherapy vaccine candidates rather than contract sterile manufacturing. A later corporate evolution included Genkyotex naming on some records. This profile is the vaccine / Pasteur spinout lineage — not the unrelated Provence CDMO also sometimes branded BT Pharma. Status closed on Dealroom.

MoreLess Source: Dealroom company data

At a glance

Status: Closed
Founded: 2001
Headquarters: Labège, France
Employees: 5
Open positions: None listed
Dealroom signal: 0.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Testing, Biotechnology, Oncology, Vaccines, Immune System, Biotech and Pharma, Hard Tech, medical testing, DT and LS, observatoire healthtech
Business model: Manufacturing
Client focus: b2b
Investment activity: 1 company, latest Dec 2016
Capital deployed: —
Preferred round: MERGER
Links: Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
MERGER✓Other financing	Feb 2017	$0	—	GenKyoTex	—
IPO✓Exit	Apr 2014	$44M	$131M	Undisclosed	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin	R&D
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Genticel website traffic

Latest recorded traffic for Genticel is 170 monthly website visits. Genticel's team grew 0% over the past year.

Latest monthly visits170 1-year team growth0%

Monthly website visitsJan 2016–Jan 2024

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
BPBiosortia PharmaceuticalsBiosortia is working on new drugs from deep access to the chemistry of the microbiome for immuno-oncology & immunological therapeutics	Dublin, United States	Operational	10	$22M	$6M
MIMIODxMIODx, a company working on biomarker diagnostics	San Jose, United States	Operational
ITImmunomic TherapeuticsImmunomic Therapeutics, Inc.	Lancaster, United States	Operational
IMImProDiaBlood-based tests for monitoring immune status	Hertsliya, Israel	Closed
BGBlueprint GeneticsUses Next Generation Sequencing (NGS) to perform diagnostics on genetic diseases	Espoo, Finland	Operational
C2C2CareDesigns therapeutic solutions based on virtual reality in order to immerse patient in an environment that creates a certain stress	Sanary-sur-Mer, France	Operational
VIVitroScanDedicated to delivering predictive diagnostic testing to support better informed treatment decisions for cancer patients	Leiden, Netherlands	Operational
MUMultiplexDXEliminating cancer misdiagnosis by launching a new diagnostic test in 2023 and operating a boutique oligo house	Rockville, United States	Operational